ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Arch Biopartners Inc

Arch Biopartners Inc (ARCH)

1.88
-0.04
(-2.08%)
Closed 20 January 8:00AM

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

Current Price
1.88
Bid
1.88
Offer
1.91
Volume
9,510
1.86 Day's Range 1.92
1.36 52 Week Range 2.56
Market Cap
Previous Close
1.92
Open
1.92
Last Trade
300
@
1.88
Last Trade Time
Financial Volume
-
VWAP
-
Average Volume (3m)
16,547
Shares Outstanding
62,598,000
Dividend Yield
-
PE Ratio
-35.40
Earnings Per Share (EPS)
-0.05
Revenue
1.98M
Net Profit
-3.33M

About Arch Biopartners Inc

Sector
Coml Physical, Biologcl Resh
Industry
Advertising Agencies
Headquarters
Toronto, Ontario, Can
Founded
2010
Arch Biopartners Inc is listed in the Coml Physical, Biologcl Resh sector of the TSX Venture Exchange with ticker ARCH. The last closing price for Arch Biopartners was $1.92. Over the last year, Arch Biopartners shares have traded in a share price range of $ 1.36 to $ 2.56.

Arch Biopartners currently has 62,598,000 shares in issue. The market capitalisation of Arch Biopartners is $120.19 million. Arch Biopartners has a price to earnings ratio (PE ratio) of -35.40.

ARCH Latest News

Arch Biopartners Announces Ontario Research Ethics Board Approval to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery-Associated Acute Kidney Injury (CS-AKI)

TORONTO, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that the University Health Network Research...

Dosing of First Patient in a Trial for LSALT Peptide is Sending Shares HIgher

This late-stage clinical trial company focuses on preventing inflammation and acute organ injury. It is developing a platform of new drugs to prevent inflammation in the kidneys, liver and lungs...

Arch Biopartners Announces Dosing of First Patient in Canada in the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

TORONTO, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that patient recruitment and dosing have begun...

Arch Biopartners Arranges Non-Brokered Private Placement

TORONTO, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) today announced it has arranged a non-brokered private placement...

Closes Units for Debt Settlement

TORONTO, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that the Company has closed a transaction that...

Units for Debt Settlement

TORONTO, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that the Company has arranged a transaction to...

Arch Biopartners Announces Alberta Health Services Approval to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery-Associated Acute Kidney Injury (CS-AKI)

TORONTO, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that Alberta Health Services (AHS) has approved...

Arch Biopartners’ Cilastatin Drug Candidate to Participate in the PONTIAC Phase II Trial Targeting Acute Kidney Injury Caused by Drug Toxins

Arch is repurposing cilastatin, a dipeptidase-1 inhibitor, as a new treatment for acute kidney injury (AKI)Cilastatin is particularly well suited to prevent AKI caused by drug toxins due to its...

Arch Biopartners Closes Non-Brokered Private Placement

TORONTO, July 30, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) today announced it has closed the non-brokered private placement...

Arch Biopartners Arranges Non-Brokered Private Placement

TORONTO, July 29, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) today announced it has arranged a non-brokered private placement...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.06-3.092783505151.941.951.83202401.92148724CS
40.15.617977528091.782.011.7138771.90497329CS
12-0.18-8.737864077672.062.11.59165471.92897414CS
260.2716.77018633541.612.21.36148921.7879115CS
520.3422.07792207791.542.561.36191961.85162807CS
156-1.72-47.77777777783.64.250.97195652.17743219CS
2600.95102.1505376340.935.30.74270761.99597729CS

ARCH - Frequently Asked Questions (FAQ)

What is the current Arch Biopartners share price?
The current share price of Arch Biopartners is $ 1.88
How many Arch Biopartners shares are in issue?
Arch Biopartners has 62,598,000 shares in issue
What is the market cap of Arch Biopartners?
The market capitalisation of Arch Biopartners is CAD 120.19M
What is the 1 year trading range for Arch Biopartners share price?
Arch Biopartners has traded in the range of $ 1.36 to $ 2.56 during the past year
What is the PE ratio of Arch Biopartners?
The price to earnings ratio of Arch Biopartners is -35.4
What is the cash to sales ratio of Arch Biopartners?
The cash to sales ratio of Arch Biopartners is 59.31
What is the reporting currency for Arch Biopartners?
Arch Biopartners reports financial results in CAD
What is the latest annual turnover for Arch Biopartners?
The latest annual turnover of Arch Biopartners is CAD 1.98M
What is the latest annual profit for Arch Biopartners?
The latest annual profit of Arch Biopartners is CAD -3.33M
What is the registered address of Arch Biopartners?
The registered address for Arch Biopartners is 27 ST. CLAIR AVENUE EAST, P.O. BOX 305, TORONTO, ONTARIO, M5V 1M1
What is the Arch Biopartners website address?
The website address for Arch Biopartners is archbiopartners.com
Which industry sector does Arch Biopartners operate in?
Arch Biopartners operates in the ADVERTISING AGENCIES sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AHRAmarc Resources Ltd
$ 0.72
(171.70%)
4.17M
OEG.HONEnergy Inc
$ 0.035
(133.33%)
14.66k
FYLFinlay Minerals Ltd
$ 0.045
(125.00%)
4.86M
CPICarlton Precious Inc
$ 0.16
(113.33%)
1,000
MVYMoovly Media Inc
$ 0.01
(100.00%)
1.5M
GAR.HGreen Arrow Resources Inc
$ 0.015
(-66.67%)
1.96k
CANDCandelaria Mining Corp
$ 0.005
(-50.00%)
553.7k
WWTWater Ways Technologies Inc
$ 0.005
(-50.00%)
79.65k
AZC.PA2ZCryptocap Inc
$ 0.045
(-50.00%)
33k
BYM.HBaymount Incorporated
$ 0.005
(-50.00%)
5k
FYLFinlay Minerals Ltd
$ 0.045
(125.00%)
4.86M
AGMRSilver Mountain Resources Inc
$ 0.05
(-9.09%)
4.23M
AHRAmarc Resources Ltd
$ 0.72
(171.70%)
4.17M
TDGTDG Gold Corp
$ 0.245
(75.00%)
4.08M
MATEBlockmate Ventures Inc
$ 0.33
(0.00%)
3.99M

Discussion

View Full Feed
MartinLutherKing MartinLutherKing 7 seconds ago
We have been deep down in the dark for many years, investors lost everything 99.999% since IPO @ $150,000 a share
RNAZ
SorcererHero70 SorcererHero70 2 minutes ago
I don’t have the exact returns but based off my experience, you are correct with your assumptions. Leveraged etfs would be much easier. Also, the time decay on the LEAPs is more substantial than some realize. Also, there is often times problems with liquidity. From my experience I think letfs would
delerious1 delerious1 2 minutes ago
Not sure why anyone would want to disrespect the retail shareholders owning a micropenny stock on the OTC-Pink market...there are over 12,000 stocks on the OTC.....easy for the uneducated to call them all a "scam" but why punish the shareholders with contempt for something obviously misunderstood...
NBRI
Trend22 Trend22 4 minutes ago
WCVC - Commanders pulled it out last night. Still in the hunt!!
Brodey79 Brodey79 4 minutes ago
Wouldn’t that be somethin. Building something special here and anyone in now is in early. Lots of room for growth and easy to scale.
FDCT
12yearplan 12yearplan 4 minutes ago
That stream of consciousness I look forward .. at and in a different time.
TucsonPhil TucsonPhil 5 minutes ago
Rumors that Musk may buy Intel. Given the Twitter/X debacle, would that be good or bad?
INTC
ChannelTrader ChannelTrader 6 minutes ago
Good stuff, brother !
The Berry Brothers !!!!!

https://www.facebook.com/blakprophetz/videos/1137189684417966
fuagf fuagf 6 minutes ago
Sheesh. The guy just doesn't learn. His problem is his darts are so magically
conceived they tumble after hitting his target, react, and rebound onto him.

https://www.youtube.com/watch?v=ZgXNVA9ngx8
Tahoe2468 Tahoe2468 7 minutes ago
So they are saying they have a product already produced coming to the US made out of Coca leaves??? And also putting a "New age is coming" I don't know if we're supposed to play Blue clues or what? But obviously they put it in quotations for some reason..... 
KRTL
al44 al44 8 minutes ago
In a word yes-

If the races were reversed it would have already happened

https://media.gettr.com/group4/getter/2025/01/19/18/9d4ff744-3cc0-e84e-1cc3-57f4340b6835/e0c83bbb945e9263dcd66fea5877a545_768x0.jpg
crazy horse 0 crazy horse 0 9 minutes ago
The Berry Brothers !!!!!

https://www.facebook.com/blakprophetz/videos/1137189684417966
cojoboy cojoboy 9 minutes ago
Sorry my man..this sucks.
IGPK
1hunglo 1hunglo 9 minutes ago
docsetc is too unknowledgeable to answer iglows posts>>docsetc has no idea of the mistakes he is making & how they will affect him being a pimp for the Cotropias as he is~imo.
ENZC
Invest-in-America Invest-in-America 10 minutes ago
BTCT: I can't stand Trump, but I hope the CRYPTOS soar monster time tomorrow. (E.g., the ONLY "crisis" on the USA's southern boarder is that there is a boarder THERE in the first place !! Long ago, the great Nation of Mexico should have become yet another USA STATE --- and same for JAPAN --- tw
BTCT
fuagf fuagf 12 minutes ago
Hopefully, yet another business failure for the up and coming greater mess as a president.
nutrader2 nutrader2 12 minutes ago
Robert Morrissey has affiliations with investment banking. He is a Director/Board Member at Gabelli Utility Trust, a diversified investment management company. Additionally, he has served as a Chairman at BSB Bancorp, Inc. and Belmont Savings Bank.
EARI
Lime Time Lime Time 14 minutes ago
It's going to be a great America. It's time to give up politics and see things for what they are: Common sense government
Tahoe2468 Tahoe2468 14 minutes ago

Interesting 
KRTL
fuagf fuagf 14 minutes ago
Good one. NO i don't mean your president.
Doc logic Doc logic 15 minutes ago
exwannabe,

The biggest problem with your argument is how old the trial was when the screening halt was put into place. There was lots of mature data from the first patients enrolled back when it was a Phase 2 and early Phase 3 at that point which offered comparative data regarding OS
CVM NWBO
tulla236a tulla236a 15 minutes ago
jimmy joe, i understand your loyalty. it’s human nature. give trump a chance to make you rich. i would have voted for any American if i thought they would change things to make ME rich. if he doesn’t come out swinging then i’m done with him.

things have to change. you have to a
AMC
vinmantoo vinmantoo 15 minutes ago
It looks like the quality of data has finally reached Big Phama's risk-reward profile.

Big pharma often wastes a lot of money.
Stern is Bald Stern is Bald 15 minutes ago
Ugly nerd does not understand news cycle hasn't even started...
FNMA
mascale mascale 17 minutes ago
Data incapability demonstration, magnified, noted: Re: Trading tomorrow. etc.
HIRU

Your Recent History

Delayed Upgrade Clock